Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026
Biodesix will present multiple datasets at CHEST 2026 showing real-world integration of its Nodify Lung blood-based lung nodule risk test into routine care pathways. New analyses from the CLARIFY study — which has enrolled more than 2,000 patients in routine practice — include PET imaging comparisons and diagnostic test sequencing, alongside independent research on follow-up adherence and proteomic risk stratification.
Key figures
- Drug Name
- Nodify Lung
- Clarify enrollment
- more than 2,000 patients
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.